Search

Your search keyword '"Radhakrishnan, Mahesh"' showing total 12 results
Start Over Author "Radhakrishnan, Mahesh" Journal indian journal of pharmacology
12 results on '"Radhakrishnan, Mahesh"'

1. Diabetes-associated depression: The serotonergic system as a novel multifunctional target

Author

Prabhakar, Visakh, Gupta, Deepali, Kanade, Prateek, and Radhakrishnan, Mahesh

Subjects
Depression (Mood disorder) -- Physiological aspects, Diabetes mellitus -- Physiological aspects, Serotonin -- Health aspects, Health
Abstract

Byline: Visakh. Prabhakar, Deepali. Gupta, Prateek. Kanade, Mahesh. Radhakrishnan Diabetes associated depression is a largely understudied field which nonetheless carries a significant disease burden. The very low therapeutic efficacy of [...]

Published
2015

2. Neuropharmacological evaluation of a novel 5-HT[sub]3 receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress parameters in mice

Author

Bhatt, Shvetank, Radhakrishnan, Mahesh, Jindal, Ankur, Devadoss, Thangaraj, and Dhar, Arghya

Subjects
Brain -- Physiological aspects, Neurological research, Antagonists (Biochemistry) -- Dosage and administration, Oxidative stress -- Research, Pharmaceutical research, Stress (Psychology) -- Drug therapy, Health
Abstract

Byline: Shvetank. Bhatt, Mahesh. Radhakrishnan, Ankur. Jindal, Thangaraj. Devadoss, Arghya. Dhar Aim: The aim of the study was to evaluate a novel 5 HT [sub]3 receptor antagonist (6g) on chronic [...]

Published
2014

3. Anti-anxiety effect of a novel 5-HT [sub]3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice

Author

Kurhe, Yeshwant, Radhakrishnan, Mahesh, Thangaraj, Devadoss, and Gupta, Deepali

Subjects
Pharmacology, Experimental, Antagonists (Biochemistry) -- Dosage and administration, Drug interactions -- Research, Anxiety -- Prevention, Health
Abstract

Byline: Yeshwant. Kurhe, Mahesh. Radhakrishnan, Devadoss. Thangaraj, Deepali. Gupta Objective: To investigate the anti-anxiety activity of '6k', a novel 5-hydroxytryptamine type 3 (5-HT [sub]3 ) receptor antagonist in in mice. [...]

Published
2014

4. Antidepressant-like activity of (4-phenylpiperazin-1-yl) (quinoxalin-2-yl) methanone (4a), a novel 5-HT3 receptor antagonist: An investigation in behaviour-based rodent models of depression

Author

Baldev Kumar, Radhakrishnan Mahesh, Ankur Jindal, Shvetank Bhatt, Dilip Kumar Pandey, and Thangaraj Devadoss

Subjects
Male, medicine.medical_specialty, medicine.drug_class, Open field, Piperazines, Head-twitch response, Mice, 5-HT3 Receptor Antagonist, Internal medicine, Quinoxalines, medicine, Animals, Serotonin 5-HT3 Receptor Antagonists, Pharmacology (medical), Rats, Wistar, 5-HT receptor, forced swim test, olfactory bulbectomy, (4-phenylpiperazin-1-yl) (quinoxalin-2-yl) methanone, Pharmacology, 4a, 5-HT3 receptor antagonist, Chemistry, Depression, Reserpine, Receptor antagonist, Antidepressive Agents, Rats, Disease Models, Animal, Endocrinology, Analysis of variance, Behavioural despair test, medicine.drug, Research Article
Abstract

Aim: The present study was designed to investigate the antidepressant potential of (4-phenylpiperazin-1-yl) (quinoxalin-3-yl) methanone (4a), a novel 5-HT 3 receptor antagonist, with an optimal log P (2.84) and pA 2 value (7.3) greater than ondansetron (6.9) using rodent behavioural models of depression. Materials and Methods: Swiss albino mice were used in actophotometer test, forced swim test (FST) and 5-hydroxytryptophan (5-HTP) induced head twitch response. Reserpine induced hypothermia (RIH) and olfactory bulbectomy were performed in male Wistar rats. Statistical analysis was carried out by using one-way analysis of variance followed by Tukey's test. Results: Acute treatment of 4a (1-4 mg/kg, i.p.) in mice produced antidepressant-like effects in FST without affecting the baseline locomotion in actophotometer test. Further, 4a (2-4 mg/kg, i.p.) potentiated the 5-HTP induced head twitches response in mice and also antagonized RIH in rats. Furthermore, sub-chronic (14 days) treatment with 4a (2-4 mg/ kg, p.o.) significantly attenuated the behavioural anomalies induced by bilateral olfactory bulbectomy in rats in modified open field exploration. Conclusions: These preliminary investigations confirm that 4a exhibits antidepressant-like activity in behaviour based rodent models of depression.

Published
2012

5. Ondansetron ameliorates depression associated with obesity in high-fat diet fed experimental mice: An investigation-based on the behavioral, biochemical, and molecular approach

Author

Yeshwant Kurhe and Radhakrishnan Mahesh

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, 5-HT3 receptor antagonist, Population, Motor Activity, Hippocampal formation, Diet, High-Fat, Serotonergic, Hippocampus, Mice, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Animals, Serotonin 5-HT3 Receptor Antagonists, Pharmacology (medical), Cyclic adenosine monophosphate, Obesity, education, Neurotransmitter, Swimming, Pharmacology, education.field_of_study, Depression, business.industry, Dentate gyrus, Body Weight, serotonergic neurotransmission, Antidepressive Agents, comorbid depression, 030104 developmental biology, Endocrinology, chemistry, Antidepressant, business, 030217 neurology & neurosurgery, Research Article, Behavioural despair test
Abstract

INTRODUCTION: Obesity is an important risk factor for depression as more than half of the obese population is susceptible for depression at double rate. Our earlier studies reported the antidepressant potential of 5-HT3receptor antagonist, ondansetron (OND) in depression associated obesity using behavioral tasks. The present research work is aimed to evaluate the effect of OND on depression associated with obesity with special emphasis on biochemical and molecular mechanisms such as hippocampal brain-derived neurotrophic factor (BDNF), cyclic adenosine monophosphate (cAMP), 5-hydroxytryptamine (5-HT), hippocampal histological examination and immunohistochemical expression of p53 proteins. MATERIALS AND METHODS: Mice were fed with high-fat diet (HFD) for 14 weeks, followed by treatment schedule for 28 days with vehicle/OND (0.5 and 1 mg/kg, p.o.)/reference antidepressant escitalopram (10 mg/kg, p.o.). Subsequently, animals were screened in the behavioral tests of depression such as forced swim test (FST) and sucrose preference test (SPT), biochemical estimations including hippocampal cAMP, BDNF and 5-HT, and molecular assays mainly histology and p53 expression of dentate gyrus (DG). RESULTS: HFD-fed mice showed increased immobility time in FST, reduced sucrose consumption in SPT, decreased level of signal transduction factor cAMP, neuronal growth factor BDNF and neurotransmitter 5-HT in the hippocampus, and raised and p53 expression neuronal damage in the DG region of mice fed with HFD in comparison to the mice fed with normal pellet diet. Chronic treatment with OND (0.5 and 1 mg/kg, p.o.) significantly inhibited the behavioral, biochemical and molecular modifications in HFD-fed mice. CONCLUSION: In the preliminary study, OND attenuated depression associated with obesity in mice fed with HFD using various assays procedures, at least in part by the modulation of serotonergic transmission.

Published
2017

6. Antidepressant-like effect of novel 5-HT3 receptor antagonist N-n-butyl-3-ethoxyquinoxalin-2-carboxamide (6p): an approach using rodent behavioral antidepressant tests

Author

Radhakrishnan Mahesh, Shvetank Bhatt, Thangaraj Devadoss, and Ankur Jindal

Subjects
medicine.medical_specialty, medicine.drug_class, Guinea Pigs, Pharmacology, In Vitro Techniques, Motor Activity, Open field, Body Temperature, Mice, 5-HT3 Receptor Antagonist, Ileum, Internal medicine, Quinoxalines, quinoxaline, medicine, 5-HT3 receptor antagonists, Animals, Serotonin 5-HT3 Receptor Antagonists, Pharmacology (medical), Rats, Wistar, Swimming, forced swim test, antidepressant, Behavior, Animal, business.industry, Receptor antagonist, Paroxetine, Olfactory Bulb, Tail suspension test, Antidepressive Agents, Rats, serotonin, Endocrinology, Hindlimb Suspension, Exploratory Behavior, Antidepressant, Serotonin, business, Behavioural despair test, medicine.drug, Research Article
Abstract

Objective: The present study was designed to investigate the antidepressant potential of N-n-butyl-3-ethoxyquinoxalin-2-carboxamide ( 6p ), a novel 5-HT 3 receptor antagonist in rodent behavioral models of depression. Materials and Methods: The compound 6p was examined in various behavioral models like forced swim test (FST), tail suspension test (TST), mechanistic models [5-hydroxytryptophan (5-HTP)-induced head twitch and reserpine-induced hypothermia (RIH)], and in chronic surgery model-olfactory bulbectomy in rats. Results: Compound 6p (1, 2, and 4 mg/kg, i.p.) exhibited antidepressant-like effect in FST and TST after acute treatment without having an effect on baseline locomotor activity. Moreover, 6p (2 mg/kg, i.p.), potentiated the 5-HTP-induced head twitch responses in mice and inhibited the RIH in rats. Chronic treatment (14 days) with 6p (1 and 2 mg/kg, p.o.) and paroxetine (10 mg/kg, p.o.) in rats significantly reversed the behavioral anomalies induced by bilateral olfactory bulbectomy using open field exploration. Conclusion: The preliminary studies reveal that compound 6p exhibits antidepressant-like effect in behavioral rodent models of depression.

Published
2013

10. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress parameters in mice.

Author

Bhatt, Shvetank, Radhakrishnan, Mahesh, Jindal, Ankur, Devadoss, Thangaraj, and Dhar, Arghya Kusum

Subjects
*NEUROPHARMACOLOGY, *OXIDATIVE stress, *MICE as carriers of disease, *LOCOMOTOR control, *LIPID peroxidation (Biology), *SUPEROXIDE dismutase
Abstract

Aim: The aim of the study was to evaluate a novel 5 HT 3 receptor antagonist (6g) on chronic stress induced changes in behavioural and brain oxidative stress parameter in mice. A complicated relationship exists among stressful stimuli, body's reaction to stress and the onset of clinical depression. Chronic unpredictable stressors can produce a situation similar to human depression, and such animal models can be used for the preclinical evaluation of antidepressants. Materials and Methods: In the present study, a novel and potential 5-HT3 receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) with good Log P (3.08) value and pA2 (7.5) values, synthesized in our laboratory was investigated to study the effects on chronic unpredictable mild stress (CUMS)-induced behavioural and biochemical alterations in mice. Mice were subjected to different stress paradigms daily for a period of 28 days to induce depressive-like behaviour. Results: The results showed that CUMS caused depression-like behaviour in mice, as indicated by the significant (P < 0.05) decrease in sucrose consumption and locomotor activity and increase in immobility the forced swim test. In addition, it was found that lipid peroxidation and nitrite levels were significantly (P < 0.05) increased, whereas glutathione levels, superoxide dismutase and catalase activities decreased in brain tissue of CUMS-treated mice. '6g' (1 and 2 mg/kg, p.o., 21 days) and fluoxetine treatment (20 mg/kg, p.o., 21 days) signficantly (P < 0.05) reversed the CUMS-induced behavioural (increased immobility period, reduced sucrose preference and decreased locomotor activity) and biochemical (increased lipid peroxidation; decreased glutathione levels, superoxide dismutase and catalase activities). However fluoxetine treatment (20 mg/kg, p.o., 21 days) significantly decreased the nitrite level in the brain while '6g' (1 and 2 mg/kg, p.o., 21 days) did not show significant (P < 0.05) effect on the nitrite levels in brain. Conclusion: Compound '6g' exerted antidepressant-like effects in behavioural despair paradigm in chronically stressed mice by restoring antioxidant mechanisms. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

11. Anti-anxiety effect of a novel 5-HT3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice.

Author

Kurhe, Yeshwant Vijay, Radhakrishnan, Mahesh, Thangaraj, Devadoss, and Gupta, Deepali

Subjects
*RECEPTOR antibodies, *SEROTONIN, *ANXIETY diagnosis, *LABORATORY mice, *LATENCY-associated nuclear antigen
Abstract

Objective: To investigate the anti-anxiety activity of "6k", a novel 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist in in mice. Materials and Methods: Anti-anxiety activity of "6k" (1, 2, and 4 mg/kg, intraperitoneally (i.p.)) was evaluated in mice by behavioral tests such as elevated plus maze (EPM), open field test (OFT), light-dark box (L&D), and hole board test (HBT). Diazepam (2 mg/kg, i.p.) served as reference standard. Results: "6k" significantly (P < 0.05) increased the time and entries in open arm in EPM as compared to vehicle control group. Further, "6k" significantly (P < 0.05) increased the central and peripheral ambulation along with rearings and time in central area; whereas, reduced the fecal pellets in OFT as compared to vehicle control group. There was significant (P < 0.05) reduction in the latency to enter dark chamber; whereas, increased number of crossings and time in light chamber in L&D aversion test by treatment with "6k" as compared to vehicle control group. In HBT, "6k" significantly (P < 0.05) increased the number of head dipping and squares crossed; whereas, reduced the latency for first head dip and number of fecal pellets as compared to vehicle control group. Conclusion: A novel 5-HT3 receptor antagonist has anti-anxiety action. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

12. Anti-anxiety effect of a novel 5-HT₃ receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice.

Author

Kurhe YV, Radhakrishnan M, Thangaraj D, and Gupta D

Subjects
Animals, Anti-Anxiety Agents pharmacology, Behavior, Animal drug effects, Male, Mice, Quinoxalines pharmacology, Serotonin Antagonists pharmacology, Thiazoles pharmacology, Anti-Anxiety Agents therapeutic use, Anxiety drug therapy, Quinoxalines therapeutic use, Receptors, Serotonin, 5-HT3 drug effects, Serotonin Antagonists therapeutic use, Thiazoles therapeutic use
Abstract

Objective: To investigate the anti-anxiety activity of "6k", a novel 5-hydroxytryptamine type 3 (5-HT₃) receptor antagonist in in mice., Materials and Methods: Anti-anxiety activity of "6k" (1, 2, and 4 mg/kg, intraperitoneally (i.p.)) was evaluated in mice by behavioral tests such as elevated plus maze (EPM), open field test (OFT), light-dark box (L&D), and hole board test (HBT). Diazepam (2 mg/kg, i.p.) served as reference standard., Results: "6k" significantly (P < 0.05) increased the time and entries in open arm in EPM as compared to vehicle control group. Further, "6k" significantly (P < 0.05) increased the central and peripheral ambulation along with rearings and time in central area; whereas, reduced the fecal pellets in OFT as compared to vehicle control group. There was significant (P < 0.05) reduction in the latency to enter dark chamber; whereas, increased number of crossings and time in light chamber in L&D aversion test by treatment with "6k" as compared to vehicle control group. In HBT, "6k" significantly (P < 0.05) increased the number of head dipping and squares crossed; whereas, reduced the latency for first head dip and number of fecal pellets as compared to vehicle control group., Conclusion: A novel 5-HT3 receptor antagonist has anti-anxiety action.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results